secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001390478-23-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS Q3 net loss $9.3M; GPS Phase 3 enrollment complete, SLS009 shows CR in AML
--------------------------------------------------------------------------------

- Net loss $9.3M ($0.33/share) vs $7.0M in Q3 2022; cash $4.0M as of Sep 30, 2023; subsequent $4.0M offering.
- Phase 3 REGAL trial of GPS in AML expected to complete enrollment (ex-China) in November 2023; interim data late 2023/early 2024.
- SLS009 Phase 2a in AML: first patient achieved complete response, six of seven patients alive; anti-leukemic effects in all.
- FDA granted Orphan Drug Designation for SLS009 in AML and Fast Track for r/r PTCL.
- Anticipating $13.0M milestone from 3D Medicines upon China enrollment in REGAL in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047823000025/0001390478-23-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047823000025/sls-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001390478-23-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer